AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04743258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAXILLARY PREMOLAR EXTRACTION
Description: Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling \& alignment.
Study NCT04743258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DISTALIZATION
Description: Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
Study NCT02349165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial versus epithelium-off CXL
Description: A comparison of the CXL procedure with and without epithelium removal
Study NCT02349165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transepithelial versus epithelium-off CXL
Description: A comparison of the CXL procedure with and without epithelium removal
Study NCT02349165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricrolin TE
Description: Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
Study NCT02349165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic riboflavin
Description: After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
Study NCT00128453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine (for 3 months)
Description: Colchicine 0.5mg BID (patients>70Kg) or 0.5mg once daily
Study NCT00128453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04085666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX 6114
Description: CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
Study NCT04085666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
Study NCT03436680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study NCT03436680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT03436680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Complete neurofeedback training sessions
Study NCT03436680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03436680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03436680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03436680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00561730 — intervention group
Intervention type: DRUG
Intervention: Pantoprazole
Description: Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
Study NCT03560375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT)
Description: Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27
Study NCT03560375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegeterranean diet (V-Med diet)
Description: The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.
Study NCT03560375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
Study NCT02642315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Horizant
Description: Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360).
Study NCT00576901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 1 of each 3 week cycle
Study NCT00576901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv on day 1 of each 3 week cycle
Study NCT00576901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: 2000mg/m2 po on days 1-15 of each 3 week cycle
Study NCT04471675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound docetaxel
Description: Albumin-bound docetaxel by intravenous infusion.
Study NCT02746952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART19
Study NCT03836066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab-Bevacizumab
Description: Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
Study NCT02426957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational enhancement therapy
Description: The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
Study NCT00004109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
Study NCT00004109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
Study NCT03510364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
Study NCT00298870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
Study NCT00298870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazed
Description: Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
Study NCT06355245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Collection of blood samples
Study NCT01345149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Description: Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling
Study NCT04111744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Exercise Training
Description: Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery
Study NCT04111744 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimal medical therapy
Description: Standard medication for stable CAD
Study NCT04111744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Description: Standard medication for stable CAD
Study NCT04597086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study NCT04597086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT04597086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bright White Light Therapy
Description: Receive BWLT
Study NCT04597086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04597086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01291303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized ventilation
Description: Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
Study NCT01291303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ventilation
Description: Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available).
Study NCT01045590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: titration
Description: Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
Study NCT01045590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: titration
Description: Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
Study NCT03619031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LONG LEAVENING
Description: a long-leavened (60 h) pizza composed of sourdough and a flour mix.
Study NCT03619031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHORT LEAVENING
Description: a short-leavened (5 h) pizza composed of sourdough and a flour mix.
Study NCT03619031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRADITIONAL
Description: a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
Study NCT00162123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Study NCT03730103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same day discharge
Description: Patients will be discharged home from the hospital on the day of her surgery.
Study NCT02626949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR Course
Description: Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
Study NCT02626949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEP Course
Description: HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
Study NCT04105881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Investigation
Description: Cross sectional intervention
Study NCT00899964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: 6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
Study NCT04438057 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CCP
Description: Randomized open label study to receive 2:1 CCP to standard of care
Study NCT01641445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate (200 mg daily)
Study NCT01641445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capusules (sugar pills
Study NCT03220919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-based
Description: Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
Study NCT03220919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose level-based
Description: Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, >10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, > 20 mmol/L.
Study NCT01242865 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention and Interpretation Therapy
Description: Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book.
Study NCT03010748 — intervention group
Intervention type: DEVICE
Intervention: Scheimpflug tomography system (Pentacam) measurement
Description: The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
Study NCT04635618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Brief-Telepsychotherapy
Description: Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
Study NCT04635618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Interpersonal Telepsychotherapy
Description: Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
Study NCT04635618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychoeducation
Description: A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
Study NCT02906709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin, 25 mg orally once weekly
Study NCT02906709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to omarigliptin orally once weekly
Study NCT02906709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
Study NCT00650936 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AMPLATZER Septal Occluder
Description: AMPLATZER Septal Occluder
Study NCT01545076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20 (low dose)
Description: 20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)
Study NCT01545076 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
Study NCT01545076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: 10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
Study NCT01545076 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IgPro10
Description: 10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
Study NCT01545076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20 (high dose)
Description: 20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)
Study NCT04502342 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycloroquine and Azythromycine
Description: dual treatment with Hydroxycloroquine and Azythromycine
Study NCT04502342 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cospherunate/Azythromycine
Description: dual treatment with Cospherunate and Azythromycine
Study NCT04502342 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cospherunate/Phytomedicine/Azythromycien
Description: triple treatment with Cospherunate, Asen and Azythromycine
Study NCT01030965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 125mcg
Description: 125mcg once-daily
Study NCT01030965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 250mcg
Description: 250mcg once-daily
Study NCT01030965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 500mcg
Description: 500mcg once-daily